Agreements

Dako, has entered into a development and collaboration agreement with Amgen to develop a diagnostic test for an Amgen cancer drug candidate targeted for a rare and deadly cancer. Over the past 6 months agreements with Bristol-Myers Squibb and Genentech  have been announced. Dako has also entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development. This agreement has been concluded two years ago.